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Thymosin beta 4 (Tβ4) was previously shown to reduce infarct size and improve contractile
performance in chronic myocardial ischemic injury via two phases of action: an acute
phase, just after injury, when Tβ4 preserves ischemic myocardium via antiapoptotic or
anti-inflammatory mechanisms; and a chronic phase, when Tβ4 activates the growth
of vascular or cardiac progenitor cells. In order to differentiate between the effects
of Tβ4 during the acute and during the chronic phases, and also in order to obtain
detailed hemodynamic and biomarker data on the effects of Tβ4 treatment suitable for
use in clinical studies, we tested Tβ4 in a rat model of chronic myocardial ischemia
using two dosing regimens: short term dosing (Tβ4 administered only during the first
3 days following injury), and long term dosing (Tβ4 administered during the first 3 days
following injury and also every third day until the end of the study). Tβ4 administered
throughout the study reduced infarct size and resulted in significant improvements in
hemodynamic performance; however, chamber volumes and ejection fractions were not
significantly improved. Tβ4 administered only during the first 3 days following injury tended
to reduce infarct size, chamber volumes and improve hemodynamic performance. Plasma
biomarkers of myocyte injury were significantly reduced by Tβ4 treatment during the
acute injury period, and plasma ANP levels were significantly reduced in both dosing
groups. Surprisingly, neither acute nor chronic Tβ4 treatment significantly increased blood
vessel density in peri-infarct regions. These results suggest the following: repeated dosing
may be required to achieve clinically measureable improvements in cardiac function
post-myocardial infarction (MI); improvement in cardiac function may be observed in the
absence of a high degree of angiogenesis; and that plasma biomarkers of cardiac function
and myocardial injury are sensitive pharmacodynamic biomarkers of the effects of Tβ4.
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INTRODUCTION
Thymosin beta 4 (Tβ4) is a widely-expressed peptide which
has been shown to regulate multiple cellular processes, includ-
ing cell migration (Malinda et al., 1997; Kobayashi et al., 2002;
Sosne et al., 2002; Bock-Marquette et al., 2004), survival (Bock-
Marquette et al., 2004; Sosne et al., 2004) and differentiation
(Huang et al., 2006; Philp et al., 2007). Tβ4 has also been impli-
cated in wound healing in a range of organs (Goldstein et al.,
2012; Sosne et al., 2012) as well as regenerative processes, most
notably vasculogenesis associated with endothelial progenitor
cells (Hinkel et al., 2010). In the heart, Tβ4 has been suggested
to play a role in cardioprotective mechanisms following ischemic
injury. Bock-Marquette et al. reported that Tβ4 treatment initi-
ated just after permanent ligation of the left anterior descending
(LAD) coronary artery in mice resulted in improved ejection
fraction 14 and 28 days post-surgery; additionally, scar volume
was reduced 28 days post-surgery (Bock-Marquette et al., 2004).
This was reported to be due to preservation of ischemic car-
diac myocytes, potentially via activation of the pro-survival Akt
pathway. A subsequent study using the same mouse model found
significant increases in coronary blood vessel growth following
Tβ4 treatment (Bock-Marquette et al., 2009). Additional mech-
anistic studies in a 7-days mouse myocardial infarction (MI)
model indicated that the PIP complex activates Akt in this set-
ting (Sopko et al., 2011). Tβ4 was reported to have qualitatively
similar effects in large animals: retroperfusion of Tβ4 increased
cardiomyocyte survival in a pig ischemia-reperfusion model of
cardiac injury, with concomitant improvements in two measures
of cardiac contractility, subendocardial segment shortening and
dP/dtmax (Hinkel et al., 2008).
Tβ4 was previously shown to dramatically reduce myocar-
dial injury following only one dose, administered directly to the
heart just after injury, by direct intra-cardiac injection (Bock-
Marquette et al., 2004; Sopko et al., 2011) and by coronary
retroperfusion (Hinkel et al., 2008). Because systemic adminis-
tration of Tβ4 would be safer and more convenient than direct
cardiac injection or retroperfusion, we measured the cardiopro-
tection resulting from repeated dosing with Tβ4 systemically,
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every day for the 3 days period immediately following the onset
of ischemia. For comparison, we also tested repeated dosing
every day for the first 3 days followed by dosing every third day
until the end of the study. Lastly, in order to verify that Tβ4
treatment would have clinical utility in the setting of ischemia-
reperfusion in addition to permanent myocardial ischemia, we
tested the effects of repeated IP Tβ4 in an ischemia-reperfusion
model.
These studies were performed in the rat, which is larger
and has more consistent coronary vessel anatomy than the
mouse. The increased size of the rat provides more mate-
rial for histological, biochemical and plasma biomarker
quantification, and facilitates detailed measurements of
cardiac physiology, potentially providing in vivo pharma-
codynamic readouts of Tβ4 efficacy. Additionally, the more
consistent coronary vessel anatomy in the rat facilitates
induction of similarly-sized infarcts using coronary artery
ligation.
METHODS
All studies were conducted in accordance with the GSK Policy on
the Care, Welfare and Treatment of Laboratory Animals and were
reviewed the Institutional Animal Care and Use Committee either
at GSK or by the ethical review process at the institution where the
work was performed.
PERMANENT OCCLUSION MODEL
After anesthesia with Nembutal [60mg/kg, intraperitoneal (IP)
injection], male Sprague-Dawley rats (250–300 g, Charles River,
Raleigh, NC) were intubated with polyethylene-190 tube and ven-
tilated with a small animal volume-controlled respirator with a
tidal volume of 10ml/kg at 90 cycles/min (Harvard Apparatus,
Holliston, MA). Rats were placed in a supine position on a heated
rat surgical table (Harvard Apparatus, Holliston, MA) to pre-
vent hypothermia during anesthesia and surgery. The heart was
exposed via sternotomy with use of a small retractor. A 7-0
suture was passed under the left anterior descending coronary
artery (LAD) 1mm below the left atrium for permanent liga-
tion of the LAD artery. The incision was closed by layers using
5-0 suture. The endotracheal tube was removed after sponta-
neous breathing recovered. Sham-operated animals underwent
a similar surgical procedure with the exception of LAD artery
ligation. Tβ4 was supplied by RegeneRx Biopharmaceuticals,
Inc. (lot # FTHYB40602B). Tβ4 was dissolved in sterile water
(HOSPIRA, Inc., Lake Forest, IL) for injection to make a solu-
tion with a Tβ4 concentration of 1.074mg/ml. Tβ4 or vehi-
cle (sterile water for injection) was administered immediately
after MI. Rats were injected with either 5mL/kg of vehicle or
5.37mg/kg Tβ4 in vehicle, intra-peritoneally (IP). One treat-
ment group received Tβ4 immediately following surgery and
for the 2 days following, then additional Tβ4 every third day
(long-term dosing). A second treatment group received Tβ4
immediately following surgery and for the 2 days following
only (short term dosing). Plasma samples were drawn 3 days
after the surgery, then at 28 days (at the end of the study).
Cardiac function and structure was evaluated at 14 and 28 days
by MRI.
ISCHEMIA-REPERFUSION MODEL
After anesthesia with Nembutal (60mg/kg, IP injection),
male Sprague-Dawley rats (250–300 g) were intubated with a
polyethylene-190 tube and ventilated with a small animal volume-
controlled respirator with a tidal volume of 10ml/kg at 90
cycles/min (Harvard Apparatus, Holliston, MA). Rats were placed
in a supine position on a heated rat surgical table (Harvard
Apparatus, Holliston, MA) to prevent hypothermia during anes-
thesia and surgery. The heart was exposed via sternotomy with
use of a small retractor. A 7-0 suture was passed under the LAD
1mm below the left atrium and tied to a non-traumatic bal-
loon occluder for occlusion and reperfusion of that artery. LAD
occlusion and reperfusion was induced by inflating and deflating
the balloon occluder. Successful performance of coronary occlu-
sion and reperfusion was verified by color change in the apex,
by observing S-T segment elevation and widening of the QRS by
ECG (ADInstruments, Colorado Springs, CO) during ischemia,
and their resolution after reperfusion. The incision was closed
by layers using 5-0 suture. The endotracheal tube was removed
after spontaneous breathing recovered. Rats were subjected to
30min of myocardial ischemia followed by 23.5 h of reperfu-
sion injury, then analyzed for infarct size and area at risk. Rats
were injected with either 5mL/kg of vehicle or 5.37mg/kg of
Tβ4 in vehicle, IP, during the ischemic period, then 2 h after
initiation of reperfusion. Two separate groups of five rats each
were subjected to 30min of ischemia followed by 4 h of reper-
fusion, then harvested for Akt analyses; these rats were injected
with either 5mL/kg of vehicle or 5.37mg/kg of Tβ4 in vehi-
cle, IP, during the ischemic period, then 2 h after initiation of
reperfusion.
HEMODYNAMIC MEASUREMENTS AND POST-MORTEM ANALYSES
At the end of study, a 2F Millar Mikro-tip catheter transducer
was inserted into the left ventricle through the right carotid
artery to measure left ventricular pressure and+dP/dtmax and—
dP/dtmin. Heart and lung weights were measured after inva-
sive hemodynamic measurements. Hearts were perfused and
fixed with 10% neutral phosphate-buffered formalin (10%NBF)
at a pressure of 90mmHg, then were kept in 10% NBF for
16–18 h before transferring to 70% ethanol for histology anal-
ysis. Hemodynamic measurements on one animal from the
short term dosing group could not be captured due to vessel
rupture.
CARDIAC MRI
Rats were anesthetized using 1.5–2.0% isoflurane (1 L/min), and
placed inside of a radio frequency coil (ID 11.6 cm) for MR imag-
ing in a 9.4T horizontal bore magnet (Bruker, Billerica, MA). A
tri-pilot Intragate FLASH scout image was acquired using the
following parameters: TE/TR = 1.3/128ms, FOV = 60mm ×
60mm, #reps = 8, 128 matrix, slice thickness = 1mm, 469
micron in plane resolution, 10 slices/orientation, TA = 1min
5 s. Coronal and sagital long axis Intragate FLASH images were
acquired using the following parameters: TE/TR = 2.06/9.1ms,
FOV = 50mm × 50mm, #reps = 160, 128 matrix, slice thick-
ness = 2mm, 391 micron in plane resolution, TA = 93 s. A series
of 2mm thick short axis (axial) images (same parameters as long
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axis images) were acquired through the entire left ventricle of the
rat heart (∼7–8 slices). Cardiac image analysis was performed
using Analyze 8.1 AVW software (AnalyzeDirect, Lenexa KS).
Axial images of the left ventricle were reconstructed to 512 × 512
pixels prior to the manual tracing of the epicardial and endocar-
dial borders of the left ventricle in both diastole and systole. The
summation of the individual axial slice volumes for the left ven-
tricle tissue (in diastole), ED lumen volume and ES lumen volume
allowed for the quantification of LVmass, EDV, ESV, and Ejection
Fraction (EF%). The formulas for the cardiac indices are: LVMass
(mg) = LV Volume ∗ 1.05 (density of cardiac tissue); EDV (ul)
= Sum of all axial lumen volumes in diastole; ESV (ul) = Sum
of all axial lumen volumes in systole; SV (ul) = (EDV-ESV);
EF% = (EDVESV)/EDV ∗ 100.
PLASMA BIOMARKER QUANTIFICATION
250 uL of whole blood was collected in EDTA via tail vein. Blood
samples were centrifuged and plasma collected and stored at−80◦
until tested. Cardiac troponins, myosin light chain and FABP3
were quantified using a cardiac injury protein quantification
kit (Meso Scale Discovery, Rockville, MD, # K15161C-1) using
manufacturer’s protocols. Pro-ANP levels were quantified using
an ELISA kit (catalog # 04-BI-20892) from ALPCO Diagnostics
(Salem, MA) using manufacturer’s protocols.
DETERMINATION OF INFARCT SIZE (PERMANENT OCCLUSION MODEL)
Transverse 2mm rings of cardiac left ventricles were formalin
fixed and processed for paraffin embedding. A 5μm section from
each ring, representing distances of 2, 4, 6, and 8mm from the
apex, were stained with Masson Trichrome for quantitative anal-
ysis of infarct size. Each ring was photographed, and infarcted
regions of the left ventricle were defined as those bordering blue
staining. For calculation of infarct volumes, the number of blue
pixels in the infarct regions from all four sections were added
together, then normalized to overall ring area from all four sec-
tions (red + blue pixels). One apical ring with no discernible
lumen was excluded from the short term dosing group. One MI-
operated animal with no evidence of infarct from the short term
dosing group was also excluded from all analyses.
BLOOD VESSEL DENSITY ANALYSIS
Automated vessel/unit area ratio counts of rat endothelial cell
antigen positive vessels were averaged from four regions of inter-
est exhibiting primarily transverse cross-sections of muscle fibers
FIGURE 1 | Tβ4 treatment reduces infarct volume in the rat 28-days
permanent LAD occlusion model, but does not significantly improve
ejection fraction. (A) Average infarct volume was significantly reduced by
repeated dosing with Tβ4. Short term-dosing with Tβ4 trended toward
reduced infarct volume, but this effect did not reach significance. Each point
represents one animal, and the horizontal line represents the average for the
group. (B) Examples of infarcts. Non-transmural infarcts often left a large
portion of surviving myocardial tissue surrounding a sub-endocardial infarct.
(C) Tβ4-treated groups trended toward a reduced incidence of transmural
infarct, but this effect did not reach statistical significance (P = 0.2, Fischer’s
test). (D) Measurement of %EF at end-of-study revealed trends toward
improved function which did not reach significance. %EF was also measured
mid-study and effects of MI and TB4 treatment were similar (not shown).
Horizontal bars in A and C represent the mean of each group. ∗∗P < 0.01 vs.
Sham, and ∗∗∗P < 0.001 vs. Sham using a one-way ANOVA and a Tukey’s
post-hoc test.
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within the proximity of the infarct. Regions of interest were pref-
erentially selected from sections 6 then 4mm from the apex
and from non-transmural in preference to transmural infarct
areas. The anti-RECA antibody used was clone HIS52 (Serotec,
Raleigh, NC).
DETERMINATION OF INFARCT SIZE/AREA AT RISK (ISCHEMIA-
REPERFUSION MODEL)
After hemodynamic measurements, the heart was excised and
perfused with saline to wash out residual blood through an aor-
tic cannula (18-gauge needle). To delineate infarcted tissues from
viable myocardium, the heart was then perfused with a 1% solu-
tion of 2,3,5-triphenyltetrazolium chloride (TTC) in phosphate
buffer (pH 7.4, 37◦C). The viable myocardium stained red, and
the infarcted myocardium stained white. To delineate the area at
risk (ischemic area), the coronary artery was then tied at the site of
the previous occlusion and the aortic root was perfused with a 1%
Evans blue dye (Sigma) in normal saline. As a result of this proce-
dure, the portion of the LV supplied by the previously occluded
coronary artery (area at risk) was identified by the absence of
blue dye, whereas the rest of the LV was stained dark blue. The
heart was frozen, after which all atrial and right ventricular tissues
were excised. The LV was cut into transverse slices, which were
photographed using a digital camera. The borders of the infarct,
ischemic and nonischemic area of heart image were traced and
measured using Image-Pro Plus and from these measurements
infarct size was calculated as a percentage of the ischemic area.
Ischemic area was calculated as a percentage of LV area.
Table 1 | Cardiac function 4 weeks after myocardial infarction.
Sham MI + Vehicle MI + Tβ4-short MI + Tβ4-long
term dosing term dosing
N 5 13 10 12
Left ventricular systolic pressure (mm Hg) 122±8 90±3** 103±2.6* 113± 3#
Left ventricular end diastolic pressure (mm Hg) 5.3±1.31 10.3±0.98** 7.7±0.46 7.1± 0.74#
Heart rate (bpm) 376±17 349±11 344±9 366± 8
dP/dtmax (mmHgs−1) 8799±505 5701±304*** 6609±251** 7704± 412†
dP/dtmin (mmHgs−1) 8157±725 4972±263** 5459±268** 6638± 301§
EDV (uL) 485±23 784±43*** 703±49** 699± 43**
ESV (uL) 158±11 419±34 350±34* 344± 41*
EF% 67.2±1.5 47.4±2.0*** 51±2.01*** 52.4± 2.7***
Data are mean ± s.e.m. Tβ4-short term dosing rats were treated with 5mg/kg/day Tβ4IP for 3 days post-MI, with the first dose administered immediately post-MI.
Tβ4-long term dosing rats were treated with 5mg/kg/day Tβ4IP for the first 3 days, then every third day up to the end of the study on day 28, with the first dose
administered immediately post-MI. *p < 0.05 vs. sham; **p < 0.01 vs. sham; ***p < 0.001 vs. sham; #p < 0.05 vs. vehicle;
§
p < 0.01 vs. vehicle; †p < 0.00 vs.
vehicle.
FIGURE 2 | MRI images showing similar cardiac structure at
systole and diastole, from mid-study (2 weeks) and at end of
study (4 weeks), among TB4-treated (bottom row) and
vehicle-treated animals (top row). Images shown are
representative images taken from the same animals at the
indicated time points.
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ANALYSIS OF AKT PHOSPHORYLATION
Tissue from rat LV was extracted and stored at −80◦ after
study. Samples (½rat LV) were placed into tubes submerged
in liquid N2 and drained of excess followed by blunt force
pulverization. Tissue was lysed with amild detergent (750 ul) con-
taining phosphatase inhibitors (Bio-Rad Bio-Plex cell lysis buffer,
Hercules, CA) vortexed and placed on ice × 15min with shaking.
Tubes were centrifuged at 2000 g × 10min and supernatant was
FIGURE 3 | Plasma levels of markers of myocyte damage 3 days post-MI
surgery. Elevations in cTnI due to MI were highly variable and did not reach
statistical significance. Elevation in cTnT due to MI was significant, but the
trend toward reduction in the MI group treated with Tβ4 was not. Elevation in
MLC and FABP3 due to MI were significantly reduced in the Tβ4 treatment
groups. Note that at the 3 days time point, dosing regimens were identical
between the long term treatment and short term treatment groups;
accordingly, data from both Tβ4 dosing regimens have been combined into
one group for analysis. ∗P < 0.05 vs. Sham using a one-way ANOVA and a
Tukey’s post-hoc test; ∗∗∗P < 0.001 vs. Sham using a one-way ANOVA and a
Tukey’s post-hoc test; #P < 0.05 vs. MI + Vehicle using a one-way ANOVA
and a Boneferroni’s post-hoc test.
Table 2 | Organ weights in Sprague-Dawley rats 4 weeks after myocardial infarction.
Sham MI + Vehicle MI + Tβ4 short MI + Tβ4 long
term dosing term dosing
N 5 13 11 12
Body weight (g) 387±17 387±11 389±12 377± 7
Heart weight (g) 1.1±0.05 1.3±0.05* 1.2±0.04 1.2± 0.03#
Right ventricular weight (g) 0.18±0.02 0.24±0.01* 0.21±0.01 0.18± 0.01#
Left ventricular weight (g) 0.88±0.04 1.01±0.03 0.95±0.03 0.95± 0.02
Tibial Length (mm) 42.1±0.67 42.0±0.29 42.0±0.19 42.1± 0.17
Heart weight/body weight (mg/g) 2.9±0.11 3.5±0.10* 3.1±0.08# 3.2± 0.07
Right ventricular weight/body weight (mg/g) 0.47±0.04 0.61±0.03* 0.53±0.01 0.48± 0.02#
Left ventricular weight/body weight (mg/g) 2.29±0.11 2.62±0.06 2.46±0.07 2.51± 0.06
Heart weight/tibial length (mg/mm) 27.0±1.28 31.7±0.98* 28.8±0.96 28.5± 0.61#
Right ventricular weight/tibial length (mg/mm) 4.3±0.39 5.6±0.30* 4.9±0.19 4.3± 0.21#
Left ventricular weight/tibial length (mg/mm) 21.0±1.05 24.0±0.67 22.7±0.80 22.5± 0.51
Data are mean ± s.e.m. Tβ4-short term dosing rats were treated with 5mg/kg/day Tβ4 IP for 3 days post-MI, with the first dose administered immediately post-MI.
Tβ4-long term dosing rats were treated with 5mg/kg/day Tβ4 IP for the first 3 days, then every third day up to the end of the study on day 28, with the first dose
administered immediately post-MI. Data are mean ± s.e.m. #p < 0.05 MI + Vehicle vs. MI + Tβ4 group. *p < 0.05 Sham vs. MI + Vehicle.
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collected and protein determined by BCS method. Lysates were
normalized to 0.2–0.9mg/ml and analyzed by MSD assay (Meso
Scale Discovery, #N45100B-1) for phospho-Akt induction.
DATA ANALYSES
Data are presented as mean ± s.e.m. unless noted otherwise. All
other comparisons were made by t-test or one-way ANOVA using
GraphPad Prism software v5.0 (GraphPad Software, San Diego,
CA), unless otherwise noted.
RESULTS
CHRONIC Tβ4 TREATMENT REDUCES INFARCT SIZE AND PRESERVES
HEMODYNAMIC FUNCTION IN THE RAT PERMANENT LAD OCCLUSION
MODEL
The first set of experiments tested the effects of Tβ4 in a 28
days, permanent LAD occlusion model of MI in the rat. We com-
pared four groups: sham-operated, MI + vehicle injection, MI +
short term dosing of Tβ4 and MI + long term dosing of Tβ4.
The short term dosing group received IP Tβ4 injections just after
MI surgery, then daily for the subsequent 2 days, at a dose of
5.37mg/kg body weight (similar to the dose per kg body weight
administered to mice in Bock-Marquette et al., 2004). The long
term dosing group received the same treatment for the first 3 days
following surgery, but then also received IP Tβ4 every 3 days until
the end of the study. All animals for this study were sacrificed 28
days after LAD occlusion.
Histological analysis showed that LAD occlusion resulted in
significant loss of myocytes and replacement fibrosis in the
infarcted area 28 days following surgery. However, Tβ4 treatment
was able to limit this injury: as measured by cross-sectional area
of four sections per heart, mean infarct volume was significantly
FIGURE 4 | Plasma pro-ANP levels 28 days post-MI surgery. Tβ4
treatment significantly reduced plasma pro-ANP levels 28 days after MI
surgery. ∗∗P < 0.01, Sham vs. MI + Vehicle; ∗∗P < 0.01, MI + Vehicle vs.
Tβ4 (short treatment); ∗∗∗P < 0.001, MI + Vehicle vs. Tβ4 (long treatment).
reduced by 43% in the long term dosing group (from 9.1 ±
0.8 to 5.2 ± 0.8%; P < 0.01) and by 29% in the short term
dosing group, although this did not reach statistical significance
(Figure 1). In 11 of the 13 vehicle-treated MI controls (11/13),
the infarct was transmural, while in the Tβ4-treatment groups
the incidence of transmural infarction tended to be lower (7/11
FIGURE 5 | Quantification of blood vessel density in regions near the
infarcts in animals receiving coronary artery ligations. (A) Tβ4 treated
groups did not display a significant increase in blood vessel density per unit
area. ∗∗∗P < 0.001 sham operated vs. MI + Vehicle (B,C) Representative
histological stains for blood vessels from treatment and control sections;
brown staining indicates RECApositive staining.
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in the short-term group and 7/12 in the long-term treatment
group). Tβ4 treatment had no effect on survival through the peri-
operative period: two animals from each group receiving LAD
occlusion died on the day following surgery. Survival in all groups
from 24 h after surgery to the end of the study was 100%.
LAD occlusion resulted in significant decreases in left ventric-
ular systolic pressure (LVSP), maximum dP/dt, and minimum
dP/dt, and increases in left ventricular end diastolic pressure
(LVEDP) (Table 1). Long-term dosing with Tβ4 was associated
with significant improvements in LVEDP, maximum dP/dt and
minimum dP/dt, demonstrating a preservation of hemodynamic
function. The short term Tβ4 dosing group displayed trends
toward improved hemodynamic measurements, but these effects
were not significant.
Ejection fractions were reduced in all MI groups, in com-
parison to sham-operated animals. The reduction in infarct
volumes in the long term Tβ4 dosed group translated into a non-
significant 5% increase in ejection fraction at 28 days (Table 1 and
Figure 1). The decrement in systolic blood pressure induced by
MI was partly attenuated by longterm Tβ4 treatment.
Additionally, transient benefits of Tβ4 treatment on cardiac
function were not observed. Analyses of MRI images taken at
14 days post-occlusion and 28 days postocclusion revealed no
other significant differences in EDV, ESV, septal wall thickness,
anterior wall thickness or posterior wall thickness among the
groups receiving MI surgery (Figure 2 and data not shown).
BIOMARKERS OF MYOCARDIAL DAMAGE ARE REDUCED BY Tβ4
TREATMENT DURING THE ACUTE PHASE OF PERMANENT
MYOCARDIAL ISCHEMIA
Plasma biomarkers of myocardial injury were measured at 3 days
post-surgical injury to determine whether Tβ4 administration
prevented myocyte loss during the acute period, just following
MI. At this time point, animals in both the long-term and the
short-term Tβ4 dosing groups had received identical doses of
Tβ4; therefore the two Tβ4 treatment groups were combined
for analysis. Plasma levels of MLC and FABP3 were significantly
elevated 3 days post MI, and this effect was attenuated by Tβ4
treatment. Trends toward reduced levels of cardiac troponins
were observed, but these effects were not significant. Additionally,
cardiac troponin I appeared elevated in the MI group, but this
elevation was not statistically significant (Figure 3).
Tβ4 ATTENUATES POST-INFARCT CARDIAC HYPERTROPHY
Tβ4 treatment tended to reduce gravimetric measurements of
cardiac hypertrophy (Table 2). This effect was small, reaching
FIGURE 6 | Tβ4 treatment reduced infarct size in a rat
ischemia-reperfusion model of myocardial injury. (A) Quantification
of area-at-risk and infarct sizes in the hearts from rats treated with
vehicle vs. rats treated with Tβ4 administered both during and after
the ischemic period. Acute treatment with Tβ4 did not affect the
area at risk. Tβ4 treatment significantly reduced infarct sizes at
23.5 h postischemic injury. (B) Table describing hemodynamic
measurements at end-of-study. End-diastolic pressures were reduced
and dP/dtmax was increased in the Tβ4-treated group in comparison
to the vehicle-treated group.
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statistical significance only in the long-term dosing group. Right
ventricular weights were significantly reduced in the long-term
dosing group. Consistent with these findings, treatment with Tβ4
reduced plasma pro-ANP levels in both short-term and long-term
treatment groups (Figure 4). Notably, plasma pro-ANP levels
were almost as low in the Tβ4-treated groups as in the sham
operated control group at 28 days.
BLOOD VESSEL DENSITY IS NOT INCREASED BY Tβ4 TREATMENT IN
THE PERIINFARCT REGION
Previous studies indicated that Tβ4 functions partly through a
pro-angiogenic mechanism (Smart et al., 2007; Bock-Marquette
et al., 2009). In order to determine whether Tβ4 stimulates angio-
genesis in the rat MI model, we quantified blood vessel density in
regions bordering the infarct. LAD occlusion resulted in signifi-
cant blood vessel rarefaction. Tβ4 treated groups did not have a
significant increase in border zone coronary capillaries in com-
parison to the vehicle-treated MI control group (Figure 5). Blood
vessel densities were not measured mid-study, and so we can-
not rule out the possibility of that Tβ4 treatment increases blood
vessel density transiently; however, as noted above, mid-study
measurements of cardiac structure and function did not reveal
significant benefits of Tβ4 treatment.
REDUCTION IN ACUTE REPERFUSION INJURY BY Tβ4
Tβ4 treatment was previously shown to activate anti-oxidant
and anti-apoptotic mechanisms in vitro (Wei et al., 2012).
In order to evaluate the cardioprotective effects of systemic
Tβ4 in an ischemia-reperfusion model (which subjects cardiac
myocytes to oxidative stress during the re-perfusion phase,) two
groups of 10 rats each were subjected to 30min of myocardial
ischemia, followed by 23.5 h of reperfusion. One group received
5.4mg/kg Tβ4 IP during the ischemic period and also 2 h
later, while the other group received only water. Tβ4 treated
animals had significantly reduced infarct size as a percentage
of area at risk in comparison to the vehicle-treated control
FIGURE 7 | TB4 treatment reduces infarct sizes without affecting
area-at-risk in the acute ischemia-reperfusion model in the rat. Shown
are representative hearts from a treatment and a control animal, sectioned
from apex to base (clockwise). White areas represent infarcted tissue; red
areas are viable, and blue tissue was not at risk of infarct. The heart from
the TB4-treated animal (right panel) shows reduced infarct sizes at multiple
levels in comparison to the heart from the vehicle-treated animal.
animals (57.9 ± 1.73% in the vehicle-treated animals, com-
pared to 44.7 ± 3.41% in the Tβ4-treated animals; p < 0.01;
Figure 6). As in the permanent ischemia model, hemodynamic
measurements of Tβ4-treated animals demonstrated signifi-
cantly preserved LVEDP and maximum dP/dt (Figure 6, lower
panel). Representative infarct area measurements are shown in
Figure 7.
ACTIVATION OF AKT SIGNALING IN INJURED MYOCARDIAL
TISSUE BY Tβ4
Activation of Akt signaling during the acute phase of ischemic
injury has been proposed as the mechanism by which Tβ4
administration protects myocardial tissue during ischemia (Bock-
Marquette et al., 2004). We assessed the level of activation of
the Akt signaling pathway during the acute phase of reperfusion
injury. At 2.5 h post-surgery, 30min following the second dose
of Tβ4, ischemic and remote LV tissue pieces were isolated. The
percentage of Akt present in the active, phosphorylated form was
modest in all groups, ranging from 3–5% of total Akt. The per-
centage of phospho-Akt in Tβ4 treated hearts was significantly
elevated in ischemic tissue, but was suppressed in tissue isolated
from non-ischemic regions of the same hearts, compared to
vehicle-treated controls (Figure 8).
DISCUSSION
Previous studies performed in the mouse found the following:
1-the majority of cardiomyocyte apoptosis induced by perma-
nent ischemia occurs within 3 days (based on the observation
that the number of apoptotic nuclei was similar between sham-
operated and coronary artery occlusion-operated mice 3 days
after surgery); and, 2-Tβ4 treatment significantly reduced the
number of apoptotic cardiomyocytes 24 h post-occlusion, indi-
cating that one mechanism by which Tβ4 reduced infarct size was
by reducing cardiomyocyte apoptosis. In the rat, the majority of
FIGURE 8 | Activation of the Akt pathway by acute administration of IP
Tβ4 in the rat ischemia-reperfusion model was significant but modest,
from 4 to 6% in post-ischemic tissues. Akt activation was reduced in
non-ischemic remote myocardial tissue from the same hearts. ∗∗P < 0.01
Vehicle (non-ischemic) vs. Tβ4 treated (non-ischemic); #P < 0.05 Vehicle
(ischemic) vs. Tβ4 treated (ischemic).
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cardiomyocyte cell loss following coronary artery permanent lig-
ation occurs within the first day after occlusion (Anversa et al.,
1998). Therefore, we hypothesized that repeated systemic treat-
ment with Tβ4 during the 3 days period immediately following
occlusion would be sufficient to provide maximal preservation
of cardiomyocyte number and cardiac function. Three days after
coronary occlusion, plasma levels of MLC and FABP3 were sig-
nificantly increased, and this increase was significantly attenuated
by Tβ4 treatment. Therefore, part of the beneficial effects of Tβ4
can be attributed to cardioprotection during the acute phase of
cardiomyocyte cell death immediately following ischemic injury.
(The levels of cTnI were highly variable at this time point:
cTnI levels were not significantly induced even comparing the
sham-operated group to the coronary artery occlusion + vehicle
treated group).
However, continued dosing of Tβ4 was required in order to
obtain significant preservation of cardiac function and reduction
in infarct volumes measured 28 days post-occlusion. Specifically,
systolic BP, diastolic BP and maximum and minimum dP/dt
were all significantly preserved by long-term Tβ4 treatment.
Consistently positive trends in cardiac function were observed in
the short term Tβ4 dosing group, but these did not reach statisti-
cal significance. Long-term dosing with Tβ4 significantly reduced
infarct size in the rat permanent MI model by 43%, roughly con-
sistent with the significant reduction in scar volume previously
observed in themouse. These results are consistent with Tβ4 play-
ing a role in maintaining the structure and function of ischemic
myocardium beyond the acute phase of cardiomyocyte cell death.
Furthermore, the beneficial effects of continued dosing of Tβ4 did
not appear to be due to activation of angiogenesis alone, as the
increases in blood vessel density in the infarct border zones of
animals treated with Tβ4 were not significant by ANOVA.
Previous studies have demonstrated a pro-angiogenic effect of
TB4 treatment in mouse hearts following MI (Bock-Marquette
et al., 2009; Sopko et al., 2011). It is not clear why in the present
study we did not observe significant cardiac angiogenesis 28
days post-MI following systemic TB4 treatment in the rat. One
possible explanation is differences in time post-infarct when cap-
illary densities were measured: previous studies performed in the
mouse were terminated at 7 days (Sopko et al., 2011) and 7–14
days (Bock-Marquette et al., 2009), while the present study was
terminated at 28 days. It is possible that TB4 treatment caused
a transient increase in or preservation of coronary blood vessels.
However, if this was the case, this transient increase in blood vessel
density was not sufficient to significantly improve %EF measured
at day 14.
Some markers of post-infarct hypertrophic remodeling were
reduced in the Tβ4 treatment groups: ANF levels 28 days post-
infarct were significantly reduced in both Tβ4 dosing groups,
as were some measures of heart weight. Although consistently
observed using both gravitometric and plasma biomarker anal-
yses, these effects were not statistically significant in all dosing
groups, or with all measurements. Furthermore, given the reduc-
tion in infarct volumes in these groups, it is not clear from current
data whether Tβ4 plays a direct role in reducing hypertrophic
responses, or the observed reductions in post-infarct hypertrophy
were secondary to reduced infarct sizes.
Tβ4 has been proposed as a treatment for cardiac reperfusion
injury (Goldstein et al., 2012). Permanent surgical occlusion of
the LAD induces myocardial ischemia only, without re-perfusion
injury. As such, permanent LAD occlusion does not serve as a
model for myocardial injuries associated with acute coronary syn-
drome patients following re-canalization. In order to evaluate the
potential clinical benefits of Tβ4 treatment in such a setting, we
tested the effects of repeated Tβ4 administration during both an
ischemic period, and then additional dosing during reperfusion.
Tβ4 treatment resulted in a significant decrease in infarct size
normalized to area-at-risk, with a concomitant improvement in
LVEDP and dP/dtmax. These results are consistent with a previ-
ous study in which intracoronary Tβ4 was administered during
ischemic cardiac injury in a pig model (Hinkel et al., 2008),
but indicate that direct coronary administration of Tβ4 is not
required to obtain these therapeutic benefits.
Tβ4 treatment during myocardial injury preserved a degree
of cardiac structure and function in multiple surgical models
in the rat. Repeated dosing with Tβ4 provided greater benefit
than dosing only just after injury. Importantly, data presented
in the current study indicate that there may be clinical benefit
stemming from systemic administration of Tβ4 during the acute
period of cardiac injury, i.e., that retroperfusion or direct intra-
cardiac injection may not be required in order to obtain benefit
measureable via hemodynamic or plasma biomarker testing.
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